- Home
- SOC vs CLDX Comparison
SOC vs CLDX Comparison
Compare SOC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | CLDX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | 200 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | SOC | CLDX |
|---|---|---|
| Price | $13.36 | $34.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $19.33 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | $234.65 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $3.72 | $17.87 |
| 52 Week High | $35.00 | $34.52 |
Technical Indicators
Market Signals| Indicator | SOC | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 66.82 |
| Support Level | $11.25 | $24.70 |
| Resistance Level | $14.77 | N/A |
| Average True Range (ATR) | 1.27 | 1.45 |
| MACD | -0.39 | 0.16 |
| Stochastic Oscillator | 18.23 | 90.62 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.